Baxter International
BAX
$18.68
+1.52%
Baxter International Inc. is a global healthcare company that provides a broad portfolio of essential medical products, including injectable therapies, IV pumps, surgical sealants, nutritional products, and hospital equipment such as beds and patient monitoring tools acquired through Hillrom. The company operates as a significant but challenged player in the medical instruments and supplies industry, with a legacy in hospital-focused consumables and capital equipment. The current investor narrative is dominated by operational headwinds and strategic repositioning, as evidenced by the recent sale of its kidney care division in early 2025 and recent news highlighting manufacturing disruptions for critical drugs in Europe and disappointing 2026 profit guidance that has pressured the stock.…
BAX
Baxter International
$18.68
Related headlines
Investment Opinion: Should I buy BAX Today?
Rating & Thesis: Hold. Baxter International represents a high-risk, potentially high-reward turnaround situation where the stock's deeply discounted valuation (PS 0.87) conflicts with severe operational challenges, creating uncertainty that warrants caution rather than conviction. Analyst sentiment is mixed with neutral ratings predominating, reflecting the lack of clarity on the company's path to sustainable profitability.
Supporting Evidence: The primary valuation metric, Price-to-Sales at 0.87, represents an extreme discount to historical levels and suggests the market has priced in significant pessimism. The forward P/E of 9.33x implies analysts expect a return to profitability with EPS of approximately $2.14, though this contrasts sharply with the trailing P/E of -10.24x. Revenue shows modest growth with Q4 2025 up 8.03% YoY to $2.97B, but profitability metrics are deeply negative with a -8.51% net margin. Positive free cash flow of $323M provides some financial flexibility, but the negative ROE of -15.61% indicates fundamental value destruction.
Risks & Conditions: The two biggest risks are continued margin compression from operational inefficiencies and failure to meet 2026 profit guidance. This Hold rating would upgrade to Buy if the company demonstrates two consecutive quarters of gross margin recovery above 25% and provides clear evidence of debt reduction, or downgrade to Sell if revenue declines YoY or the stock breaks below the $15.73 support level. Relative to its own history, the stock appears undervalued, but relative to its current fundamentals, it appears fairly valued given the operational challenges.
Sign up to view all
BAX 12-Month Price Forecast
Baxter presents a classic value trap versus turnaround opportunity dichotomy. The extremely low PS ratio of 0.87 suggests either extraordinary value or accurately priced fundamental deterioration. The forward P/E of 9.33x indicates the market expects significant profit recovery, but recent Q4 results with a $1.13B loss and margin collapse to 19.4% raise serious doubts about execution. The stock's 11% bounce from oversold levels suggests value investors are testing, but the primary downtrend remains intact. The stance would upgrade to bullish with two consecutive quarters of margin improvement above 25% and debt reduction, or downgrade to bearish on a break below $15.73 support with deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Baxter International's 12-month outlook, with a consensus price target around $24.28 and implied upside of +30.0% versus the current price.
Average Target
$24.28
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$15 - $24
Analyst target range
Consensus sentiment is mixed with limited coverage, as only 8 analysts provide estimates for the stock. The distribution of recent institutional ratings shows a lack of strong conviction, with actions like 'Neutral' from Citigroup and Goldman Sachs, an 'Overweight' from Barclays, and an 'Underweight' from Morgan Stanley, alongside a downgrade from 'Buy' to 'Hold' by Argus Research in late 2025. The average target price is not provided in the data, so the implied upside or downside cannot be calculated, indicating insufficient data to gauge a clear consensus price target. The range of analyst estimates shows moderate uncertainty, with EPS estimates for the upcoming period spanning from $1.98 to $2.31 around an average of $2.14, and revenue estimates clustered tightly between $11.88B and $11.91B. The high EPS target likely assumes successful execution and margin improvement, while the low target may factor in continued operational disruptions and cost pressures. The recent pattern of neutral ratings and one downgrade suggests analysts are cautious and awaiting clearer signs of a fundamental turnaround before becoming more bullish.
Bulls vs Bears: BAX Investment Factors
The evidence currently favors the bear case, as the company's severe profitability issues and operational disruptions outweigh its deeply discounted valuation. The most critical tension in the investment debate is whether Baxter's current PS ratio of 0.87 represents an extraordinary value opportunity or accurately reflects a business in structural decline. The resolution hinges on whether management can execute a turnaround that stabilizes margins and returns the company to sustainable profitability, as implied by the forward P/E of 9.33x, or if the Q4 2025 losses signal deeper, persistent problems. The recent 11% bounce from oversold levels suggests some value investors are testing the waters, but the stock remains 41% below its 52-week high with significant fundamental headwinds.
Bullish
- Deeply Undervalued Price-to-Sales Ratio: The stock trades at a trailing PS ratio of 0.87, at the absolute bottom of its historical range and signaling extreme market pessimism. This valuation suggests the market is assigning minimal value to Baxter's $11.9B revenue stream, potentially creating a deep value opportunity if operations stabilize.
- Strong Liquidity and Positive Free Cash Flow: The company maintains a robust current ratio of 2.31 and generated $323M in TTM free cash flow, providing a buffer against operational headwinds. This liquidity supports ongoing operations and strategic repositioning despite significant quarterly losses.
- Analyst Expects Return to Profitability: The forward P/E of 9.33x, based on an average EPS estimate of $2.14, implies a strong market expectation for a return to profitability in the next 12 months. This contrasts sharply with the trailing P/E of -10.24x, indicating a potential inflection point if guidance is met.
- Recent Price Bounce from Oversold Levels: The stock has rebounded 11.12% over the past month from near its 52-week low of $15.73, suggesting a potential oversold relief rally. Trading at just 26% of its 52-week range ($15.73-$32.04), the stock is in deep value territory with limited technical downside if support holds.
Bearish
- Severe Profitability Crisis and Margin Collapse: Q4 2025 saw a catastrophic net loss of $1.13B and a gross margin collapse to 19.4% from a trailing 30.1%, indicating severe operational distress. The quarterly operating margin of -24.5% and TTM net margin of -8.51% show the company is destroying shareholder value.
- High Financial Leverage and Negative ROE: A debt-to-equity ratio of 1.63 indicates elevated financial leverage that compounds risks during operational challenges. The negative return on equity of -15.61% confirms the company is not generating adequate returns on invested capital.
- Disappointing 2026 Guidance and Supply Disruptions: Recent news highlights manufacturing disruptions for critical cancer drugs in Europe and disappointing 2026 profit guidance that pressured the stock. These operational headwinds create significant near-term uncertainty about the company's turnaround timeline.
- Persistent Long-Term Downtrend and Underperformance: The stock has declined -38.83% over the past year, underperforming the S&P 500 by -67.04 percentage points, indicating deep-seated fundamental concerns. Despite a recent bounce, the stock remains in a primary downtrend with resistance at the 52-week high of $32.04.
BAX Technical Analysis
The stock is in a pronounced long-term downtrend, with a 1-year price change of -38.83%, significantly underperforming the S&P 500's +28.21% gain. Currently trading at $18.78, the price sits near the lower end of its 52-week range of $15.73 to $32.04, positioning it at approximately 26% of this range, which suggests deep value territory but also reflects persistent negative momentum and fundamental concerns. Recent momentum shows a short-term bounce, with a 1-month price increase of 11.12%, which contrasts sharply with the longer-term declines of -7.81% over 3 months and -38.83% over 1 year. This divergence indicates a potential oversold relief rally or mean reversion attempt, though it remains within the context of a broader bear market, as evidenced by a deeply negative 1-year relative strength of -67.04 against the market. Key technical levels are clearly defined, with immediate support at the 52-week low of $15.73 and major resistance at the 52-week high of $32.04. A sustained breakdown below $15.73 would signal a new leg down, while a move above $32.04 would be needed to invalidate the primary downtrend. The stock's beta of 0.62 indicates it is 38% less volatile than the broader market, which is atypical for a stock with such a large drawdown and suggests its declines are more idiosyncratic, driven by company-specific issues rather than sector-wide volatility.
Beta
0.62
0.62x market volatility
Max Drawdown
-50.4%
Largest decline past year
52-Week Range
$16-$32
Price range past year
Annual Return
-36.8%
Cumulative gain past year
| Period | BAX Return | S&P 500 |
|---|---|---|
| 1m | +8.5% | +5.4% |
| 3m | -1.8% | +10.9% |
| 6m | +1.1% | +11.0% |
| 1y | -36.8% | +28.1% |
| ytd | -4.2% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BAX Fundamental Analysis
Revenue growth is modest but inconsistent, with Q4 2025 revenue of $2.97 billion representing an 8.03% year-over-year increase; however, segment data shows Medical Products and Therapies ($1.39B) is the largest contributor, followed by Healthcare Systems and Technologies ($827M) and Pharmaceuticals ($668M). The quarterly trend reveals volatility, with revenue growing from $2.63B in Q1 to $2.97B in Q4, but profitability has been severely impaired, casting doubt on the quality of this top-line growth. Profitability is deeply negative, with the company reporting a net loss of $1.13 billion and a gross margin of only 19.4% in Q4 2025, a severe compression from the 30.05% trailing gross margin, indicating significant cost pressures or one-time charges; the operating margin was -24.5% for the quarter, and the trailing twelve-month net margin is -8.51%, showing the company is far from sustainable profitability. The balance sheet and cash flow present a mixed picture: the company maintains a strong current ratio of 2.31, indicating good short-term liquidity, but carries a high debt-to-equity ratio of 1.63, signaling elevated financial leverage. Trailing twelve-month free cash flow is positive at $323 million, providing some internal funding capability, but the negative return on equity of -15.61% indicates the company is destroying shareholder value despite generating some operational cash.
Quarterly Revenue
$3.0B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.19%
Latest Quarter
Free Cash Flow
$323000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BAX Overvalued?
Given the negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.87, which is exceptionally low and suggests the market is assigning minimal value to Baxter's revenue streams, likely due to the severe profitability issues. There is no forward PS provided for comparison, but the forward PE of 9.33x implies the market expects a return to profitability, creating a stark contrast with the deeply negative trailing PE of -10.24x. Compared to industry averages, data is not available in the provided dataset for a direct sector PS comparison; however, a PS of 0.87 is generally considered very low for a healthcare equipment company, indicating a significant discount that the market is applying due to Baxter's operational challenges and losses. Historically, Baxter's own PS ratio has fluctuated wildly, from a high of 14.46 in Q1 2021 down to the current 0.87. The current PS is at the absolute bottom of its multi-year historical range, suggesting the stock is pricing in extreme pessimism or fundamental deterioration; this could represent a deep value opportunity if operations stabilize, but it also reflects the high risk that current challenges are structural rather than cyclical.
PE
-10.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -64x~149x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Baxter faces severe financial risks from its profitability crisis, with Q4 2025 gross margins collapsing to 19.4% from a trailing 30.1% and a net loss of $1.13B for the quarter. The company carries significant leverage with a debt-to-equity ratio of 1.63, which increases financial strain during operational challenges. Revenue concentration in hospital-focused products makes the business vulnerable to healthcare spending cycles, while recent manufacturing disruptions for cancer drugs in Europe highlight ongoing operational instability.
Market & Competitive Risks: The stock trades at a historically low PS ratio of 0.87, but this discount reflects justified concerns about structural issues rather than temporary headwinds. Recent news indicates rising petrochemical costs from geopolitical tensions could further pressure margins for medical supplies. With a beta of 0.62, the stock exhibits defensive characteristics but has still underperformed the market by 67 percentage points over the past year, suggesting company-specific rather than sector-wide problems are driving the decline.
Worst-Case Scenario: The most damaging scenario would involve continued operational deterioration where Baxter fails to stabilize margins, faces additional manufacturing disruptions, and misses already-disappointing 2026 guidance. This could trigger further analyst downgrades, debt covenant concerns given the 1.63 debt-to-equity ratio, and a breach of the $15.73 support level. Realistic downside could reach -16% to the 52-week low of $15.73, with potential for further decline if the company's cash position deteriorates from the current $323M in TTM free cash flow. Historical maximum drawdown of -50.44% shows the stock's vulnerability to severe sell-offs during operational crises.
FAQ
The primary risks are: 1) Financial risk from severe profitability issues, with Q4 2025 gross margins collapsing to 19.4% and a $1.13B quarterly loss, compounded by high leverage (debt-to-equity of 1.63). 2) Operational risk from recent manufacturing disruptions for cancer drugs in Europe and disappointing 2026 profit guidance. 3) Competitive/market risk from potential margin pressure due to rising petrochemical costs highlighted in recent news. 4) Technical risk with the stock down -38.83% over the past year and trading near 52-week lows, suggesting persistent negative momentum. The profitability crisis represents the most immediate and severe risk to shareholder value.
The 12-month outlook presents three scenarios with associated probabilities. The base case (50% probability) targets $19-25, assuming gradual operational improvement and meeting of reduced 2026 guidance. The bull case (25% probability) targets $26-32, requiring successful turnaround execution and margin recovery. The bear case (25% probability) targets $15-18, involving further operational deterioration and a break below the $15.73 support. The forward P/E of 9.33x suggests analysts expect EPS of approximately $2.14, but recent quarterly volatility makes this forecast highly dependent on management's ability to stabilize operations in the coming quarters.
BAX appears statistically undervalued based on traditional metrics but may be fairly valued given its operational challenges. The trailing PS ratio of 0.87 is at the absolute bottom of its historical range and suggests the market is assigning minimal value to Baxter's $11.9B revenue stream. However, the forward P/E of 9.33x implies the market expects a significant profit recovery to approximately $2.14 EPS. Compared to its own history, the stock is cheap, but relative to its current fundamentals—including a -8.51% net margin and -15.61% ROE—the valuation reasonably reflects the company's profitability crisis.
BAX represents a high-risk, potentially high-reward situation that is only suitable for risk-tolerant investors comfortable with turnaround stories. The stock trades at a deeply discounted PS ratio of 0.87, suggesting significant upside if operations stabilize, but recent Q4 2025 results showing a $1.13B loss and margin collapse to 19.4% indicate severe challenges. With analyst sentiment mixed and no clear consensus price target, the stock is best approached cautiously. For investors with a multi-year horizon who can withstand volatility, a small position might be justified, but most investors should wait for clearer signs of operational improvement before committing capital.
BAX is unsuitable for short-term trading given its low beta of 0.62 (reducing volatility-based trading opportunities) and lack of near-term positive catalysts. The stock is best approached as a potential long-term turnaround story with a minimum 2-3 year horizon, allowing time for operational improvements to materialize. The company's essential healthcare products provide some business stability, but the path to profitability recovery will require multiple quarters of execution. Dividend investors should note the modest 3.5% yield, but the negative payout ratio suggests dividend sustainability depends on profit recovery. Only investors with patience and risk tolerance should consider BAX for their portfolio.